Zobrazeno 1 - 10
of 476
pro vyhledávání: '"E Domènech"'
Autor:
M.G. Álvarez-Morujo de Sande, R. González-Aguado, G. Guerra-Jiménez, E. Domènech-Vadillo, H. Galera-Ruiz, E. Figuerola-Massana, Á. Ramos-Macías, C. Morales-Angulo, A.J. Martín-Mateos, E. Domínguez-Durán
Publikováno v:
Journal of Otology, Vol 14, Iss 3, Pp 111-116 (2019)
Background: Probable benign paroxysmal positional vertigo, spontaneously resolved (pBPPVsr), is a variant of benign paroxysmal positional vertigo (BPPV) in which there is no observable nystagmus and no vertigo with any positional maneuver. Objectives
Externí odkaz:
https://doaj.org/article/097cdb20d4254a5f98ba26484f4d147b
Autor:
M Chaparro, M García Donday, S Riestra, A J Lucendo, J M Benítez, M Navarro-Llavat, J Barrio, V J Morales-Alvarado, M Rivero, D Busquets, E Leo Carnerero, O Merino Ochoa, O Nantes Castillejo, P Navarro, M Van Domselaar, A Gutiérrez Casbas, I Alonso-Abreu, R Mejuto, L Fernández Salazar, M Iborra, M D Martín-Arranz, J R Pineda, M J Sampedro, K Serra Nilsson, A Bouhmidi Assakali, L Batista, C Muñoz Villafranca, I Rodríguez-Lago, D S Ceballos Santos, I Guerra, M Mañosa, I Marín Jimenez, I Vera Mendoza, M Barreiro-de Acosta, E Domènech, M Esteve, V García-Sánchez, P Nos, J Panés, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i50-i54
Background Background: The feasibility of anti-TNF discontinuation in inflammatory bowel disease (IBD) must be proven in clinical trials including patients in clinical, endoscopic, and radiologic remission at the time of anti-TNF withdrawal to make r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8acd9ed996ae8e4fcd0df9c8a1758fb8
https://doi.org/10.1093/ecco-jcc/jjac190.0037
https://doi.org/10.1093/ecco-jcc/jjac190.0037
Autor:
R Suau, E Pardina, M D López-Tejero, V Lorén, Y Zabana, M Llaves, B Cordobilla, F Cañete, M Guasch, D Ricart-Jané, M Mañosa, E Domènech, J C Domingo, J Manyé
Publikováno v:
Journal of Crohn's and Colitis. 17:i192-i194
Background Crohn’s disease (CD) is an inflammatory bowel disease (IBD) of complex etiology that normally requires bowel resection. However, many patients suffer from post-operative recurrence (POR) within one year. Here, the inflammatory and bacter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ab1984e53cfe3d784c85f7fc374bdc04
https://doi.org/10.1093/ecco-jcc/jjac190.0153
https://doi.org/10.1093/ecco-jcc/jjac190.0153
Autor:
M J García, M Rivero, A Fernández-Clotet, R de Francisco, B Sicilia, F Mesonero, M L de Castro, M J Casanova, F Bertoletti, F J García Alonso, A López García, B Julián, X Calvet, M Barreiro-de Acosta, L Jara, P Varela, A Nuñez, E Ricart, S Riestra, L Arias, M Rodríguez, L Arranz, R Pajares, R Mena, M Calafat, P Camo, L Jiménez, A Ponferrada, R E Madrigal, J Llao, E Sesé, P Almela, L Codesido, S de la Maza, C Leal, E Sánchez, J R Pineda Mariño, E Domènech, M Chaparro, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 16:i121-i123
Background Main aim: To evaluate the retention rate of ustekinumab compared to vedolizumab in Crohn’s disease patients who failed anti-TNF therapy in clinical practice. Secondary aims: To compare the short-term and long-term effectiveness, and the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bb25a476f697966c8266af70fdf372f
https://doi.org/10.1093/ecco-jcc/jjab232.117
https://doi.org/10.1093/ecco-jcc/jjab232.117
Autor:
I Guerra Marina, F Barros, M Chaparro, J M Benítez, M D Martín Arranz, R de Francisco, M Piqueras, L de Castro, A Y Carbajo, F Bermejo, M Mínguez, A Gutiérrez, F Mesonero, F Cañete, C González-Muñoza, M Calvo, B Sicilia, E Alfambra, C A Tardillo, M Rivero, A J Lucendo, L Bujanda, M Van Domselaar, P Almela, L Ramos, M Fernández Sánchez, E Hinojosa, C Verdejo, A Gimenez, I Rodríguez-Lago, N Manceñido, J L Pérez Calle, M D P Moreno, P G Delgado-Guillena, B Antolín, P Ramírez de la Piscina, M J Casanova, Á Carracedo, E Domènech, J P Gisbert
Publikováno v:
Journal of Crohn's and Colitis. 17:i1018-i1019
Background Treatment with thiopurines may be associated with different adverse effects, including acute pancreatitis. Risk factors for developing pancreatitis due to thiopurines in patients with Inflammatory Bowel Disease (IBD) are not clearly identi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2d90e0b599cba979a0207044c716a2e5
https://doi.org/10.1093/ecco-jcc/jjac190.1035
https://doi.org/10.1093/ecco-jcc/jjac190.1035
Autor:
P Sanz Segura, F Gomollón, S García García, M Vela, A Fernández-Clotet, R Muñoz, I García de la Filia, M García Prada, J A Ferrer Rosique, M J García, R de Francisco, L Arias, J Barrio, I Guerra, A Ponferrada Diaz, J P Gisbert, M Carrillo-Palau, X Calvet, L Márquez-Mosquera, B Gros, F Cañete, D Monfort, R E Madrigal, O Roncero, V Laredo, M Montoro, C Muñoz, B López-Cauce, R Lorente, A Fuentes, P Vega, D Martín, J Nerín de la Puerta, P Varela, D Casas-Deza, P Martínez, R Pajares, A J Lucendo, E Domènech, S García-López
Publikováno v:
Journal of Crohn's and Colitis. 17:i774-i775
Background Some patients with Inflammatory Bowel Disease (IBD) who are treated with anti-TNFα therapy develop a drug-induced psoriasis (IP) as an adverse event. There are some therapeutic approaches, being more frequent to change the biologic therap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94d31c0e6f2e2b8198e98b255073e5e7
https://doi.org/10.1093/ecco-jcc/jjac190.0773
https://doi.org/10.1093/ecco-jcc/jjac190.0773
Autor:
M Calafat Sard, I Pascual, P Nos, J Barrio, A Gutiérrez, M D Martín-Arranz, E Ricart, F Gomollón, M Sierra Ausín, J M Huguet, J Guardiola, I Vera, P Varela, E Iglesias, E Garcia-Planella, L de Castro, M F García Sepulcre, B Sicilia, L Fernández-Salazar, X Calvet, F Muñoz, S García-López, F Bermejo, L Ramos, P Martínez Montiel, R Lorente, J L Cabriada, M Piqueras, I Marín-Jiménez, M Esteve, F Mesonero, E Sesé, J P Gisbert, L Márquez, D Busquets, R Pajares, F Cañete, M Mañosa, E Domènech
Publikováno v:
Journal of Crohn's and Colitis. 17:i766-i767
Background The use of ustekinumab (UST) and vedolizumab (VDZ) as first line therapy for inflammatory bowel disease (IBD) is increasing due to safety reasons and contraindications of anti-TNFs. However, there are no studies evaluating their efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::33fe84d94dea3853b1770f3ecc70d8fc
https://doi.org/10.1093/ecco-jcc/jjac190.0764
https://doi.org/10.1093/ecco-jcc/jjac190.0764
Publikováno v:
Journal of Crohn's and Colitis. 17:i557-i558
Background Mesalazine is the most widely used maintenance therapy for ulcerative colitis (UC). The lowest effective dose recommended is 2g/day, although higher doses are often prescribed. Fecal calprotectin (FC) is a monitoring biomarker that correla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::86ac89c71bf5303bc60caa9e7139bd8e
https://doi.org/10.1093/ecco-jcc/jjac190.0560
https://doi.org/10.1093/ecco-jcc/jjac190.0560
Autor:
I Guerra Marina, L Bujanda, M Mañosa, I Pérez-Martínez, M J Casanova, L de la Peña, M de Benito, M Rivero, P Varela, L Bernal, A C Franco, Y Ber, M Piqueras, C Tardillo, Á Ponferrada, S Olivares, A J Lucendo, P Gilabert, M Sierra Ausín, M Bellart, A Herrarte, M Calafat, R de Francisco, J P Gisbert, J Guardiola, E Domènech, F Bermejo
Publikováno v:
Journal of Crohn's and Colitis. 17:i519-i520
Background An increased risk of lymphoma has been described in patients with Inflammatory Bowel Disease (IBD). The aims of our study were to determine the clinical presentation of lymphoma, previous exposure to immunosuppressive and biologic therapie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c91e018fcc1b2945ee37906b304be03
https://doi.org/10.1093/ecco-jcc/jjac190.0516
https://doi.org/10.1093/ecco-jcc/jjac190.0516
Autor:
M I Iborra Colomino, A Garrido Marín, B Caballol Oliva, J M Huguet Malavés, L Arias García, F Mesonero Gismero, S J Fernández Prada, M M Boscá Watts, Á Ponferrada Díaz, X Calvet Calvo, A Gutiérrez Casbas, I Ordás Jiménez, L Ruiz Sanchez, B Sicilia Aladren, I Garcia de la Filia, E Domènech Morral, P Nos Mateu
Publikováno v:
Journal of Crohn's and Colitis. 17:i517-i518
Background Recently, a subcutaneous formulation of biosimilar infliximab (CT-P13) (SC-IFX) has been approved for inflammatory bowel disease (IBD). The aims of this study were to evaluate efficacy, safety, pharmacokinetics and patient experience follo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c71a5fbe50c93ef27fa5894654b922c0
https://doi.org/10.1093/ecco-jcc/jjac190.0513
https://doi.org/10.1093/ecco-jcc/jjac190.0513